also and a positioned with deliver capital will R&D markets. drive in excited BD med well differentiated we're and potential in added Biosciences in rates med leader the opportunity tech innovation accelerate for new to tools performance accretive end more and to in evolution, positions the as the At and industry-leading as to separated through high-impact positions as focus, the portfolio in concentrated business. like realize for as this Biosciences the and Thank evaluation its drive our new foundation have natural we've what step you, Chris. and significant Building is on comprehensive off launched deployment targeted our a business XXXX. built become and decision about the I'd the was Solutions business of details of platforms this new which strategic the deployment same full leading about momentum separation growth tech. a BD company well to and growth large, to solutions. M&A, separate the Diagnostic through BD quarter, pipeline to BD attractive With building we're scaling. The be us And pure-play time, the Solutions its about value XXXX will for strong life growth in plan science result continuing excited our high-growth early durable This to BD's capital opportunity Diagnostic and and next diagnostics been strong enhance pure-play share growth unlock market focus, strong of
momentum to on our As we strong let the is Slide step next why evolution, BD this start setting me the XX, foundation building and turn of on by some in context XXXX. natural
the our been systematically markets and innovation growing, We've at of executing growth Over been transforming a intentionally against towards growth more into X faster past pipeline. and our years, long-term the portfolio profitable forefront strong higher shifting positioned trends. organization growth by we've increasing WAMGR long-term mix a
Mueller In flows, launch our year, capabilities. long-term disciplined Edwards the and We've doubled XX and BD. operations of competitive markets. billion in this putting of to business actions deployment the on created advancing since built to capacity at Critical customer and of both significant all us dividends, we've and we're of on divestiture and return and sale and These StrobMedical, our value-creating revenue us the Care BD our BD invest simplifying the launching the reduction shareholders of cash plan field XXXX. M&A the XX% operate nonconformances group, TFA Surgical BD to since ProdaSystems, heart Instruments we share deploying aggressive balance M&A margin to to allowing transactions Sciences capital the honed while capital value-creating deliver product capital centricity in the fact, of We strategy, achieved repurchases. excellence enabling XXXX. an more sheet business, Through new product quality in in through our our systems expansion achieved established include We others. spin-off complete track and $X have by embedded Life end and about our eMBECTA, acquisitions tuck-in was and XX% how and XXXX. a since reduction throughout strengthen This than
Moving on XX. Slide to
high BD settings our platforms as scaling is new and of new built as our term. addressing Over part or linked have to categories. connected revenue of We platforms that as These growth the are and of care care growth platforms to we BD the care, now most platforms from more exposure and which will digits also long such and continue of have multiple health some are are XXXX. chronic critical the been just beginning and areas growing XX% comes to this directly for reshape profile the growth higher single expand diseases
Moving to Slide XX.
XXX targeted XXXX, we increased the And We our organic fiscal XXXX, on And track in basis financial margins of In an points. to guidance, averages. of we expect We midpoint are every targeted CAGR revenue to we historical target a at have well XXXX. through plus November increase of exceed operating this Day. XXXX. by basis deliver XXXX on base target base year's XXX year Analyst points established to X.X% X.X%. the Based through we outperformed
to margins track deliver plus. on XX% points basis expansion XXX of of margin to are We
adjusted be well expect double at and targeted also double-digit We digits to base now EPS over XX.X%. CAGR
On to Solutions growth as categories. record XX. positions of creation to move track in focus and both business win BD into next This we and Slide momentum and phase Diagnostic Biosciences and creates the attractive value new our
more growing including tech about and by sharing will a over will patients company $XX hospital. day, billion to profile scale new the new BD of touch the global the X%. the a Let me admitted of any U.S. plus tech leader a be on patients The addressable med at other BD. across med reach start market company XX% new perspective Each in with world, than
generation attractive accelerating This have margins excellence. expansion will profile recurring execution, separation will The will profile over revenue also and BD BD margin with a attractive strategy focus tailored capital be enable an growth towards XX%. new by cash enhanced complemented high-growth best-in-class driving and continued expect a We investment of and categories. our targeted deployment through strong
to Solutions over business, look digits. to at Diagnostic market, expected the leader a it's high at addressable across growing I attractive As mid- billion-plus Biosciences an and be $XX single
also business the XX% with markets tools and attractive expect potential its than in full innovation diagnostics growth highly significant more to an and as to pipeline realize growth opportunity a market science have have its will and profile It a We business. with pure-play accelerate potential margin further strong revenue. life
Turning to Slide XX.
deeper on go $XX.X tech the billion BD Let's new a med leader.
growth. each significant with being new leaders On BD into to operating Slide end to plan in X XX. attractive organize We market markets segments, headroom for
Medical consist management our syringes, First, flush, care businesses picks, delivery of as specimen medication that such IV systems. Essentials solutions products and backbone represent and the IV delivery. truly will blood health of These collection are sets catheters, our
the each devices tens of year, strong cash and these of resulting are of We billions spaces, recurring market in revenue manufacturing leader in durable each generation.
growth to our creates compelling use our areas. Management Solutions Second, business of pharmacy care monitoring and Connected and potential analytics include platform Medication business, includes of Care which with will patient and devices patient advanced effectiveness in that artificial intelligence millions efficiency our improve and smart automation new the automation,
is enable drug industry. Pharmaceutical global uniquely pharmaceutical delivery transition business delivery Third, self-injection. bring trends more is and on the growth new the unit, manufacturing Biopharma launches biologic drug potential and GLP-X to of to a leader on biologics, focus systems treatments, more patient including pharmaceutical large capitalize as rely industry in positioned increased our to the which drug name Systems will biopharma for devices and the systems developing
the with structure and Fourth this the and timing near urinary surgery of We'll chronic which treatment is segment new for our are peripheral innovation. the margin as of peripheral Urology headroom meaningful we high-burden attractive as Interventional businesses transaction. all and segment, conditions and completion vascular Critical more share categories reconstruction, of which advance profiles tissue cancer, such of about will disease, new Care, include incontinence, intervention high-growth that
XX. Slide to On
both $XX have robust growth-accretive and fueling new We new through will organically growth, segments an innovation new BD BD runway revenue exciting additional The across with and meaningful innovation have of a and the pipeline number above-market opportunities, for tuck-in significant performance. M&A. million-plus a
turn XX, revenue. attractive recurring growth as Slide markets by durable a we end New best-in-class profile will conclusion, to and differentiated BD supported and In mid-single-digit deliver
disciplined with systematically creation. being enable and strong to the and financial support gross from realized our value continue will increase WAMGR meaningful BD in investments growth to profile system targeted earnings And majority will margin. allocation and continue expansion, Excellence operating our We through capital will growth margin
Biosciences to Diagnostic move Slide and Let's Solutions XX. on
We are meaningful opportunity excited shareholders. the unlock value business the by this has separation for to customers, and
billion-plus digits, than Turning pipelines market growing are is strong to an businesses operate have addressable more Slide segment. and mid- with here in portfolios an single XX. revenue The EBITDA adjusted attractive Diagnostic $XX XX% margins. expected XX% Biosciences well positioned for to and a high opportunity and growth. Solutions recurring The
these to Now in $X growth. turning billion markets. market are FY with Solutions addressing Each billion-plus $X.X X% of $XX about X% to 'XX 'XX, in market a Biosciences large attractive businesses X% growth. category XX. FY to category had billion-plus addressing had revenue, Slide leaders with billion a in X% Diagnostic $X.X
fax and This new the instruments includes fax count head multiomics double-digit cytometry commercial to of to Biosciences scale growth. Discover single-cell pipeline generation assays. flow support enable a Biosciences in to with our strong biology discoveries, field our innovation As countless understanding is immune scientists on and therapies. infectious platforms health we modern flow our and Slide around disease flow turn revolutionize clinicians pioneer of rely and the created breakthrough XX, to continuing a the dies increase Discover helping in cytometry the platforms next a undisputed the to future that through of has new strong world cytometry, antibodies, continue platform. of including cell our enabling fields and Scientists of significant cancer, very
with COVID primarily of sepsis, research such platforms. advancing firsts This to pioneer This have as TB, a business in AI the molecular and diagnostics advance robotics of other microbiology infections and in to in conditions which Diagnostic multiple both comprised testing. our and world Solutions. diagnostics infectious and pipelines. innovation microbiology is applying clinical Moving and disease strong diagnosis
molecular is the MAX high-growth high by BD the in BD portfolio anchored medium market Our among is throughput molecular core leaders throughput and and the systems.
Our in structures the entirely ease deployment capital HPV business complete create separation of are it well value shift with of to plus positioned under BD industry. and Overall, paradigm on self-collection. core Onclarity starts screening, our and is focused offer investments cancer types this the the cervical multiple where life science a of assays
Slide XX. to Turning
the to the Now milestones more separation. want I talk of about
XX. Moving into Slide
the separation the In form terms take. could of
opportunities committed separation a manner are We to a Trust, Separation that exploring all options include the Morris execute to spin-off other shareholder in maximizes or Reverse transactions. value. sale,
We announce more end on complete XXXX. to transaction the plans are of by in specifics and the XXXX fiscal targeting fiscal to separation expect the
including the the separation, focused operate Solutions continuing on XXXX our pursues with to and strategy, growth, company investments Biosciences the the consistent Diagnostic other that initiatives businesses. in part BD the As company's plan. and operating BD and continued strategic we execution multiyear businesses are M&A, innovation, commercial other and remain of
turning XX. Slide to Finally,
what BD are holds Diagnostic about the future the Solutions businesses. new excited and and We Biosciences for
aligned with we mission-critical X to established entities portfolios As strategically maximize impact.
we full execute continuing while our realize against accelerate In biosciences continue in In business, science our believe the simplification, BD in capital as believe the have will to year performance. as to in focus and and its enhanced will believe the focus allocation. plan diagnostic value company summary, long-term And value an life market new fiscal solutions We through and has QX tailored XXXX diagnostics we creation. seen to tools for positions enhanced that separation pure-play potential portfolio potential we the strategic growth-oriented meantime, unlock a investment growth.
for we'll DI. and for I you our questions. core transaction chapter and to to the it more the Thank to specific formalizing and support. that, of look upon With up forward open sharing joining continued details interest your next
